Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorTopaloğlu Demir, Filiz
dc.contributor.authorPolat Ekinci, Algün
dc.contributor.authorAytekin, Sema
dc.contributor.authorTopkarcı, Zeynep
dc.contributor.authorKaradağ, Ayşe Serap
dc.date.accessioned2023-01-30T11:35:13Z
dc.date.available2023-01-30T11:35:13Z
dc.date.issued2023en_US
dc.identifier.citationAytekin, S., Topkarcı, Z., Topal, O., & Karadağ, A. S. (2023). Clinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemic. Journal of Cosmetic Dermatology.en_US
dc.identifier.issn1473-2130
dc.identifier.urihttps://doi.org/10.1111/jocd.15638
dc.identifier.urihttps://hdl.handle.net/20.500.12294/3193
dc.description.abstractBackground: Since psoriasis is a chronic disease, it is not recommended to discontinue the treatment agents used. However, in real life, the treatment of psoriasis patients may be interrupted for various reasons. During the pandemic period, the treatment of many patients was also interrupted. Objectives: To evaluate relapse and clinical worsening in psoriasis patients whose biological therapy was interrupted during the pandemic and reveal associated factors. Methods: The study included patients aged ≥18 years, who were followed up with moderate and severe chronic psoriasis controlled by the last biological agent [Psoriasis Area Severity Index (PASI) 75 response achieved] but had to discontinue their treatment during the pandemic. The patients' demographic and clinical characteristics, clinical course after the discontinuation of these agents, presence of clinical worsening, and relapse were evaluated. Risk factors were analyzed with the logistic regression analysis. Results: The study included 169 patients, with a mean age of 47.3 ± 14.5 (18–87) years. The mean biologics-free time was 18.2 ± 12.3 (2–56) weeks. Clinical worsening was detected in 41.4% and relapse in 48.5% of the patients. The significant risk factors for clinical worsening and relapse in both univariate and multivariate analyses were alcohol use during the biologics-free period, total time off biologics, and the presence of an additional triggering factor. The use of secukinumab and ustekinumab was found to be a protective factor against clinical worsening in multivariate analyses. Conclusion: As the biologics-free period is prolonged, the likelihood of clinical worsening and relapse increases, therefore, we do not recommend discontinuing biological agents. © 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.en_US
dc.language.isoengen_US
dc.publisherJohn Wiley and Sons Incen_US
dc.relation.ispartofJournal of Cosmetic Dermatologyen_US
dc.identifier.doi10.1111/jocd.15638en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMedical Therapyen_US
dc.subjectPsoriasisen_US
dc.subjectTreatmenten_US
dc.titleClinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemicen_US
dc.typearticleen_US
dc.departmentTıp Fakültesi, Dahili Tip Bilimlerien_US
dc.authorid0000-0003-4333-8274en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthorKaradağ, Ayşe Serap
dc.authorscopusid26425048800en_US
dc.identifier.scopus2-s2.0-85146251492en_US
dc.identifier.pmid36630728en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster